Crinetics Pharmaceuticals, Inc. (CRNX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Crinetics Pharmaceuticals, Inc. (CRNX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 42/100 — a percentile rank of Crinetics Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $9.0B |
| P / S | 213.8× |
| EV / EBITDA | -16.4× |
| Gross margin | 96.6% |
| Operating margin | -1302.5% |
| Net margin | -1189.9% |
| Return on equity | -42.1% |
| ROIC | -48.3% |
| Revenue growth | 2928.4% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Crinetics Pharmaceuticals, Inc. overvalued? P/S looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Crinetics Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact